Evidence map›Paper›PMID 25869758›Full record

ArticleWiener klinische Wochenschrift2016

Can circulating M30 and M65 levels be beneficial markers in the diagnosis and management of patients with complete hydatidiform mole?

Adnan Incebiyik, Mehmet Vural, Hakan Camuzcuoglu, Abdullah Taskin, Aysun Camuzcuoglu, Nese Gul Hilali, Nurten Aksoy

Abstract read
PubMed Publisher
In one paragraph

Article in Wiener klinische Wochenschrift, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Molecular Basis of Hydatidiform Moles-A Systematic Review.International journal of molecular sciences · 2024
    Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Adnan IncebiyikFaculty of Medicine, Department of Gynecology and Obstetrics, Harran University, Yenisehir Campus, 63300, Sanliurfa, Turkey. dr.aincebiyik@gmail.com.
Mehmet VuralFaculty of Medicine, Department of Gynecology and Obstetrics, Marmara University, Istanbul, Turkey.
Hakan CamuzcuogluFaculty of Medicine, Department of Gynecology and Obstetrics, Harran University, Yenisehir Campus, 63300, Sanliurfa, Turkey.
Abdullah TaskinFaculty of Medicine, Department of Biochemistry, Harran University, Sanliurfa, Turkey.
Aysun CamuzcuogluFaculty of Medicine, Department of Gynecology and Obstetrics, Harran University, Yenisehir Campus, 63300, Sanliurfa, Turkey.
Nese Gul HilaliFaculty of Medicine, Department of Gynecology and Obstetrics, Harran University, Yenisehir Campus, 63300, Sanliurfa, Turkey.
Nurten AksoyFaculty of Medicine, Department of Biochemistry, Harran University, Sanliurfa, Turkey.
Harran University · TRMarmara University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe objective of this study is to evaluate the prognostic value of M30 and M65 levels as markers of apoptotic activity and maternal serum oxidative stress in patients with complete hydatidiform mole (CHM).

methodsIn total, 68 pregnant women were included in the study. The study group included 34 pregnant with CHM, while 34 healthy pregnant were employed as a control group. Venous blood samples were drawn to assess the maternal serum oxidative stress and M30-M65 levels. In addition, a second blood sample was drawn from patients with CHM on day 8 after dilatation evacuation.

resultsMaternal serum oxidative stress and M30-M65 levels were found to be significantly higher in patients with CHM as compared with the control group. It was found that serum β-subunit of human chorionic gonadotropin (β-hCG) level had a significant positive correlation with M30-M65 levels in patients with CHM. In addition, serum M65 level was found to be as effective as β-hCG in the identification of the patients with CHM.

conclusionOur results indicated that oxidative stress and apoptosis may play significant roles in CHM development. In addition, it seems that serum M30-M65 levels can presumably be an ancillary laboratory test to β-hCG in the diagnosis and follow-up of the patients with CHM.

Indexed as

AdultBiomarkersCase-Control StudiesDiagnosis, DifferentialFemaleHumansHydatidiform MoleKeratin-18Peptide FragmentsPregnancyProspective StudiesReactive Oxygen SpeciesReproducibility of ResultsSensitivity and SpecificityUterine NeoplasmsBiomarkersKeratin-18M30 cytokeratin-18 peptide, humanM65 antigen, humanPeptide FragmentsReactive Oxygen SpeciesApoptosisComplete hydatidiform moleM30 levelM65 levelβ-hCG

Identifiers

PMID25869758
OpenAlexW2050112916

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.